Page 24 - 南京医科大学自然版
P. 24
第45卷第2期
·164 · 南 京 医 科 大 学 学 报 2025年2月
tin 大大增强了Vemurafenib 对黑色素瘤细胞M229R [7] KANG T H,PARK J H,YANG A,et al. Annexin A5 as
和 M238R 的杀伤能力。Sorafenib 是多靶点受体酪 an immune checkpoint inhibitor and tumor⁃homing mole⁃
氨酸激酶抑制剂,也可作为铁死亡诱导剂应用到肝 cule for cancer treatment[J]. Nat Commun,2020,11(1):
癌 靶 向 治 疗 中 [18- 19] 。 本 研 究 发 现 敲 除 或 敲 减 1137
[8] WOODWARD A,FARIAG N F,HARRISON R G. Annexin
ANXA5能促进铁累积和脂质过氧化的病理改变,明
A5 as a targeting agent for cancer treatment[J]. Cancer
显增强铁死亡诱导剂RSL3或Erastin 对黑色素瘤细
Lett,2022,547:215857
胞的杀伤效应,提示了ANXA5可能成为促进肿瘤靶
[9] DOLL S,PRONETH B,TYURINA Y Y,et al. ACSL4
向增敏的新的潜在靶点,能协同诱导铁死亡介导的 dictates ferroptosis sensitivity by shaping cellular lipid
肿瘤细胞死亡与化疗药物、分子靶向药等联用,可 composition[J]. Nat Chem Biol,2017,13(1):91-98
能为黑色素瘤治疗提供新的临床视野。 [10] HASSANNIA B,VANDENABEELE P,VANDEN BER⁃
利益冲突声明: GHE T. Targeting ferroptosis to iron out cancer[J]. Cancer
所有作者声明无利益冲突。 Cell,2019,35(6):830-849
Conflict of Interests: [11]GAO Y L,ZHANG H J,WANG J W,et al. Annexin A5
The authors declare no competing interests. ameliorates traumatic brain injury⁃induced neuroinflam⁃
作者贡献声明: mation and neuronal ferroptosis by modulating the NF⁃κB/
王嘉慧和李璐琪完成生信分析、及大部分实验;张悦完 HMGB1 and Nrf2/HO⁃1 pathways[J]. Int Immunophar⁃
成Western blot和qPCR验证;张肖文参与补充数据和论文修 macol,2023,114:109619
改,张晶设计总体实验,分析数据,并撰写了论文。 [12] YUAN H,LI X M,ZHANG X Y,et al. Identification of
Author’s Contributions: ACSL4 as a biomarker and contributor of ferroptosis[J].
WANG Jiahui and LI Luqi performed the majority of exper⁃ Biochem Biophys Res Commun,2016,478(3):1338-
iments and completed bioinformatics analysis. ZHANG Yue 1343
[13] WU J,MINIKES A M,GAO M H,et al. Intercellular
completed Western blot and qPCR experiments. ZHANG Xiaow⁃
interaction dictates cancer cell ferroptosis via NF2⁃YAP
en participated in the supplementary data and helped the manu⁃
signalling[J]. Nature,2019,572(7769):402-406
script writing. ZHANG Jing designed the experiments,analyzed
[14]SHALHOUT S Z,YANG P Y,GRZELAK E M,et al. YAP⁃
the data,and wrote the manuscript.
dependent proliferation by a small molecule targeting
[参考文献]
annexin A2[J]. Nat Chem Biol,2021,17(7):767-775
[1] DIXON S J,LEMBERG K M,LAMPRECHT M R,et al. [15]KAN C F K,SINGH A B,DONG B,et al. PPARδ activa⁃
Ferroptosis:an iron⁃dependent form of nonapoptotic cell tion induces hepatic long⁃chain acyl⁃CoA synthetase 4 ex⁃
death[J]. Cell,2012,149(5):1060-1072 pression in vivo and in vitro[J]. Biochim Biophys Acta,
[2] ZHANG C,LIU X Y,JIN S D,et al. Ferroptosis in cancer 2015,1851(5):577-587
therapy:a novel approach to reversing drug resistance[J]. [16]WU L,LIU C J,CHANG D Y,et al. The attenuation of
Mol Cancer,2022,21(1):47 diabetic nephropathy by annexin A1 viaregulation of lipid
[3] GAGLIARDI M,SAVERIO V,MONZANI R,et al. Fer⁃ metabolism through the AMPK/PPARα/CPT1b pathway[J].
roptosis:a new unexpected chance to treat metastatic mel⁃ Diabetes,2021,70(10):2192-2203
anoma?[J]. Cell Cycle,2020,19(19):2411-2425 [17] TSOI J,ROBERT L,PARAISO K,et al. Multi⁃stage dif⁃
[4] SCHUTTERS K,REUTELINGSPERGER C. Phosphati⁃ ferentiation defines melanoma subtypes with differential
dylserine targeting for diagnosis and treatment of human vulnerability to drug ⁃ induced iron ⁃ dependent oxidative
diseases[J]. Apoptosis,2010,15(9):1072-1082 stress[J]. Cancer Cell,2018,33(5):890-904
[5] ZHANG X R,SONG L L,LI L,et al. Phosphatidylserine [18]XU F L,WU X H,CHEN C,et al. SLC27A5 promotes
externalized on the colonic capillaries as a novel pharma⁃ sorafenib⁃induced ferroptosis in hepatocellular carcinoma
cological target for IBD therapy[J]. Signal Transduct Tar⁃ by downregulating glutathione reductase[J]. Cell Death
get Ther,2021,6(1):235 Dis,2023,14(1):22
[6] VANGESTEL C,PEETERS M,OLTENFREITER R,et [19]LI Z J,DAI H Q,HUANG X W,et al. Artesunate synergizes
al. In vitro and in vivo evaluation of[99mTc]⁃labeled with sorafenib to induce ferroptosis in hepatocellular
tricarbonyl His⁃annexin A5 as an imaging agent for the carcinoma[J]. Acta Pharmacol Sin,2021,42(2):301-310
detection of phosphatidylserine⁃expressing cells[J]. Nucl [收稿日期] 2024-08-23
Med Biol,2010,37(8):965-975 (本文编辑:戴王娟)

